TOPICA Pharmaceuticals is a Palo Alto-based clinical research stage company developing luliconazole, a broad-spectrum topical antifungal agent for onychomycosis. The company raised $27M in a Series B to advance luliconazole toward late-stage testing. TOPICA plans a Phase 2b/3 trial of approximately 300 patients with mild-to-moderate distal subungual onychomycosis of the toenail. The trial is slated to start in the first half of 2012 and will involve about 20 U.S. centers. Greg Vontz serves as president and CEO, and Third Rock Ventures’ Charles Homcy will join the board in conjunction with the financing.

Total raised

$27M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2011